1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2022 Financial Results
May 12, 2022 16:10 ET | Timber Pharmaceuticals
Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022  BASKING RIDGE, NJ, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis
April 28, 2022 08:00 ET | Timber Pharmaceuticals
Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the next 60 days BASKING RIDGE, NJ, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results
March 31, 2022 17:44 ET | Timber Pharmaceuticals
Company Plans to Initiate Phase 3 Study for TMB-001 in Q2 2022 BASKING RIDGE, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting
March 25, 2022 08:00 ET | Timber Pharmaceuticals
Sub-analysis of the Phase 2b CONTROL study in congenital ichthyosis demonstrates treatment success with TMB-001 regardless of subtype BASKING RIDGE, NJ, March 25, 2022 (GLOBE NEWSWIRE) -- via...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001 in Moderate to Severe Congenital Ichthyosis
February 03, 2022 08:00 ET | Timber Pharmaceuticals
- Full data from Phase 2b CONTROL study presented at 2022 Winter Clinical Dermatology Conference - - Company plans to initiate Phase 3 study in second quarter of 2022 - BASKING RIDGE, NJ, Feb....
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference
January 06, 2022 08:00 ET | Timber Pharmaceuticals
Virtual Conference on January 10-13, 2022 BASKING RIDGE, NJ, Jan. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR),...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001
November 17, 2021 16:18 ET | Timber Pharmaceuticals
Call to be held on Monday, November 22nd at 10:00am ET BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2021 Financial Results
November 15, 2021 16:15 ET | Timber Pharmaceuticals
Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Raise of $17.25 Million Announced Subsequent to Quarter End  BASKING RIDGE, NJ, Nov. 15, 2021 (GLOBE NEWSWIRE) --...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Closing of Exercise of Underwriter’s Option to Purchase Additional Common Stock
November 09, 2021 16:05 ET | Timber Pharmaceuticals
Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million Basking Ridge, NJ, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Announces Closing of $15 Million Public Offering
November 05, 2021 16:05 ET | Timber Pharmaceuticals
Basking Ridge, NJ, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire --Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...